Bed Bath & Beyond stock jumps as Marcus Lemonis becomes CEO and pitches “Everything Home” plan
5 January 2026
1 min read

Bed Bath & Beyond stock jumps as Marcus Lemonis becomes CEO and pitches “Everything Home” plan

Murray, Utah, January 5, 2026, 09:22 MST

  • Bed Bath & Beyond named Executive Chairman Marcus Lemonis as CEO, effective Jan. 1
  • The company said Chief Operating Officer Alexander Thomas’ employment ended on the same date
  • Lemonis outlined a three-part strategy spanning retail, financial services and home transaction platforms

Bed Bath & Beyond said on Monday it has appointed Executive Chairman Marcus Lemonis as chief executive officer, with its shares up nearly 5% in premarket trading. 1

The move concentrates leadership as the retailer tries to broaden its business beyond selling home goods online and in stores. Lemonis is pitching a shift into home services and financing-related offerings, a bet that could bring in steadier fees than traditional retail.

The timing also matters because Bed Bath & Beyond is leaning into deal-making and integration work this year, while consumer demand for big-ticket home spending remains sensitive to interest rates and housing turnover.

A regulatory filing showed the board appointed Lemonis as CEO on Dec. 30, effective Jan. 1, and said the company plans to enter into an employment agreement with him, with terms to be disclosed later. 2

The filing also said the employment of Chief Operating Officer Alexander Thomas was terminated on the effective date, and that he is expected to stay on as an adviser during a transition period. 3

In a letter to shareholders, Lemonis said the company is working to become an “Everything Home” business that spans products, services and technology. “This is not a turnaround story. It is a rebuild into something structurally better,” Lemonis wrote. 4

He pointed to recent operating improvements, citing a more than 90% year-over-year improvement in net loss in the third quarter of 2025 and an improvement of more than 80% in adjusted EBITDA — a profit measure that strips out interest, taxes and some non-cash or one-off items.

Lemonis also said gross margins have generally run in the 24% to 26% range, while marketing expense has been about 13% to 14% of revenue. He said the company eliminated more than $50 million of annualized fixed operating expenses during the year and aims to remove another $25 million over the next 12 months, largely through merger-related cost savings.

He said the pending Kirkland’s transaction is expected to add about $350 million of net revenue, and framed a base revenue of roughly $1.5 billion for 2026. He also said the company expects to pursue acquisitions and investments over the next 12 months, while noting it had about $200 million in cash at the end of the third quarter of 2025.

Lemonis’ three “pillars” include omnichannel retail — integrating stores and digital channels — plus financial and insurance products and a suite of home transaction tools. That push sets Bed Bath & Beyond against entrenched rivals for home spending such as Wayfair and Williams-Sonoma, and leaves it competing in categories where Amazon is also a dominant seller.

Stock Market Today

NASA’s SPHEREx spots interstellar comet 3I/ATLAS flaring on its way out — and the chemistry surprised scientists

NASA’s SPHEREx spots interstellar comet 3I/ATLAS flaring on its way out — and the chemistry surprised scientists

7 February 2026
WASHINGTON, Feb 7, 2026, 15:17 (EST) NASA’s SPHEREx space telescope spotted interstellar comet 3I/ATLAS brightening sharply in December 2025, weeks after the comet passed closest to the sun and as it began its exit from the solar system. The infrared data showed a surge of gas and dust, including water vapor, carbon dioxide and carbon-bearing compounds, NASA said. 1 Interstellar objects are rare, and NASA says 3I/ATLAS is only the third such body confirmed, traveling on a hyperbolic path — an open orbit that does not loop back around the sun. The comet poses no threat to Earth and will
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Baidu stock slides as Kunlunxin Hong Kong IPO plan shifts focus to timing, approvals
Previous Story

Baidu stock slides as Kunlunxin Hong Kong IPO plan shifts focus to timing, approvals

Boeing stock edges up as Venezuela shock lifts defense names; BA traders eye payrolls next
Next Story

Boeing stock edges up as Venezuela shock lifts defense names; BA traders eye payrolls next

Go toTop